Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.-论文-万方医学网

作者： Laura,Collett ^[1] ; Dena R,Howard ^[1] ; Talha,Munir ^[2] ; Lucy,McParland ^[1] ; Jamie B,Oughton ^[3] ; Andy C,Rawstron ^[4] ; Anna,Hockaday ^[1] ; Claire,Dimbleby ^[1] ; David,Phillips ^[1] ; Kathryn,McMahon ^[1] ; Claire,Hulme ^[5] ; David,Allsup ^[6] ; Adrian,Bloor ^[7] ; Peter,Hillmen ^[2]

作者单位： Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. ^[1] St James' Institute of Oncology, St James' University Hospital, Leeds, UK. ^[2] Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. J.Oughton@leeds.ac.uk. ^[3] Haematological Malignancy Diagnostic Service, St James' Institute of Oncology, St James' University Hospital, Leeds, UK. ^[4] Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. ^[5] Hull York Medical School, Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust, Cottingham, UK. ^[6] Department of Haematology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK. ^[7]

主题词腺嘌呤(Adenine);青少年(Adolescent);成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);费用效益分析(Cost-Benefit Analysis);疾病恶化(Disease Progression);无病生存(Disease-Free Survival);药费支出(Drug Costs);女(雌)性(Female);人类(Humans);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);男(雄)性(Male);中年人(Middle Aged);肿瘤, 残余(Neoplasm, Residual);哌啶类(Piperidines);蛋白激酶抑制剂(Protein Kinase Inhibitors);吡唑类(Pyrazoles);嘧啶类(Pyrimidines);生活质量(Quality of Life);时间因素(Time Factors);治疗结果(Treatment Outcome);青年人(Young Adult)

DOI 10.1186/s13063-017-2138-6

PMID 28830517

发布时间 2024-02-10

检索历史清除

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

Trials

相似文献

Trials

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.

Trials

相似文献

Trials

相关期刊

检索历史清除